Caplin Point Laboratories Share Price

Audio Recording of Earnings call for the Quarter ended June 30, 2026

• BSE India
• 6 days 8 hours ago

Conference Call with Caplin Point Laboratories Management and Analysts on Q1FY27 Performance and Outlook. Listen to the <a href="https://youtu.be/bsYWq2yxPFA">full earnings transcript</a>. <br>

• Trendlyne
• 6 days 8 hours ago

<h3><span style="font-size:16px;"><strong>Pharmaceuticals company Caplin Point Laboratories announced Q1FY27 results</strong></span></h3> <p _ngcontent-ng-c1940132427=""><strong _ngcontent-ng-c1940132427="">Consolidated Financial Highlights:</strong></p> <ul> <li _ngcontent-ng-c1940132427=""><strong _ngcontent-ng-c1940132427="">Revenue from operations:</strong> The company reported revenue from operations of Rs 610.36 crore in Q1FY27, an increase of 19.63% YoY from Rs 510.22 crore in Q1FY26 and a growth of 1.70% QoQ from Rs 600.16 crore in Q4FY26.</li> <li _ngcontent-ng-c1940132427=""><strong _ngcontent-ng-c1940132427="">Total Revenue:</strong> Total revenue stood at Rs 643.91 crore in Q1FY27, up 20.73% YoY compared to Rs 533.36 crore in Q1FY26 and up 2.45% QoQ compared to Rs 628.52 crore in Q4FY26.</li> <li _ngcontent-ng-c1940132427=""><strong _ngcontent-ng-c1940132427="">EBITDA:</strong> EBITDA reached Rs 247.03 crore in Q1FY27, reflecting a growth of 22.96% YoY from Rs 200.90 crore in Q1FY26 and 6.20% QoQ from Rs 232.60 crore in Q4FY26.</li> <li _ngcontent-ng-c1940132427=""><strong _ngcontent-ng-c1940132427="">Profit Before Tax (PBT):</strong> The company recorded a PBT of Rs 225.22 crore in Q1FY27, up 22.10% YoY from Rs 184.46 crore in Q1FY26 and a 5.52% QoQ increase from Rs 213.44 crore in Q4FY26.</li> <li _ngcontent-ng-c1940132427=""><strong _ngcontent-ng-c1940132427="">Net Profit after Tax (PAT):</strong> Net profit for Q1FY27 was Rs 179.09 crore, showing an 18.79% YoY increase from Rs 150.76 crore in Q1FY26 and a 3.59% QoQ growth from Rs 172.88 crore in Q4FY26.</li> <li _ngcontent-ng-c1940132427=""><strong _ngcontent-ng-c1940132427="">Earnings Per Share (EPS):</strong> Basic EPS for Q1FY27 was Rs 23.27, an increase from Rs 20.10 in Q1FY26.</li> </ul> <p _ngcontent-ng-c1940132427=""><strong _ngcontent-ng-c1940132427="">Standalone Financial Highlights:</strong></p> <ul> <li _ngcontent-ng-c1940132427=""><strong _ngcontent-ng-c1940132427="">Revenue from operations:</strong> Standalone revenue for Q1FY27 was Rs 202.95 crore, up 11.16% YoY from Rs 182.57 crore in Q1FY26 and up 6.06% QoQ from Rs 191.36 crore in Q4FY26.</li> <li _ngcontent-ng-c1940132427=""><strong _ngcontent-ng-c1940132427="">Total Income:</strong> Total standalone income stood at Rs 265.74 crore in Q1FY27, a 23.83% YoY increase from Rs 214.60 crore in Q1FY26.</li> <li _ngcontent-ng-c1940132427=""><strong _ngcontent-ng-c1940132427="">Net Profit:</strong> The standalone net profit for the quarter was Rs 120.38 crore in Q1FY27, compared to Rs 85.89 crore in Q1FY26 (up 40.16% YoY) and Rs 120.81 crore in Q4FY26 (marginal decline of 0.36% QoQ).</li> </ul> <p _ngcontent-ng-c1940132427=""><strong _ngcontent-ng-c1940132427="">Business Highlights:</strong></p> <ul> <li _ngcontent-ng-c1940132427=""><strong _ngcontent-ng-c1940132427="">Segment Performance:</strong> <ul> <li _ngcontent-ng-c1940132427=""><strong _ngcontent-ng-c1940132427="">Rest of the World (Emerging Markets):</strong> This segment recorded revenue of Rs 476.07 crore in Q1FY27 compared to Rs 403.53 crore in Q1FY26. The segment results (PBT) were Rs 158.40 crore in Q1FY27.</li> <li _ngcontent-ng-c1940132427=""><strong _ngcontent-ng-c1940132427="">USA:</strong> Revenue from the US market reached Rs 134.29 crore in Q1FY27, up from Rs 106.69 crore in Q1FY26. The segment results (PBT) showed a significant jump to Rs 33.27 crore in Q1FY27 from Rs 9.86 crore in Q1FY26.</li> </ul> </li> <li _ngcontent-ng-c1940132427=""><strong _ngcontent-ng-c1940132427="">Emerging Markets Update:</strong> The company won emergency tenders across Central America amounting to USD 7 million to be supplied over the next two quarters. In Chile, tenders to the tune of USD 12 million were won for supply over the next 18 months.</li> <li _ngcontent-ng-c1940132427=""><strong _ngcontent-ng-c1940132427="">Mexico Operations:</strong> Caplin received four additional product approvals in Mexico and plans to file for another 120+ products in the next 18 months.</li> <li _ngcontent-ng-c1940132427=""><strong _ngcontent-ng-c1940132427="">Caplin Steriles Limited (CSL):</strong> The subsidiary currently has 60 ANDAs approved and 5 under review. CSL has launched 38 products in the US to date and plans 12 more launches in FY27.</li> <li _ngcontent-ng-c1940132427=""><strong _ngcontent-ng-c1940132427="">Strategic Growth Initiatives:</strong> Caplin Point has allocated an enhanced Capex budget of approximately Rs 1,000 + crore for investment projects, with around 50% nearing completion. These projects include an Oncology API facility (Target Q4FY27) and an OSD and COL Injectable facility (Target Q1FY28).</li> <li _ngcontent-ng-c1940132427=""><strong _ngcontent-ng-c1940132427="">Dividends:</strong> The Board recommended a Final Dividend of Rs 4/- (200%) per equity share of Rs 2/- each for FY26. An interim dividend of Rs 4/- was already paid in June 2026.</li> <li _ngcontent-ng-c1940132427=""><strong _ngcontent-ng-c1940132427="">Cash Position:</strong> As of June 30, 2026, free cash reserves stood at Rs 1,502 crore with total liquid assets at Rs 2,875 crore.</li> </ul> <p><strong>C.C. Paarthipan, Chairman, said:</strong> We are pleased to begin FY27 on a strong and encouraging note, with the Company delivering healthy growth across both our Emerging Markets and the US, while continuing to strengthen the foundations for sustainable long-term growth. Our Q1 performance reflects the consistency of our strategy, the resilience of our business model and the disciplined execution across our expanding portfolio and geographies. The continued momentum in Latin America, the accelerating contribution from the US, and the progress across our manufacturing, R&D and backward-integration initiatives reinforce our confidence in the opportunities ahead. At the same time, our strong balance sheet and substantial liquidity provide us with the flexibility to continue investing in capacity, capabilities and new markets. As we move forward, our focus remains firmly on building a more integrated, diversified and future-ready pharmaceutical platform, while creating enduring value for all our stakeholders.</p> <p><a class="lb" href="/get-document/post/pdf/5782838/" target="_blank">Result PDF</a></p>

• Trendlyne
• 6 days 11 hours ago